Lappoxo (Omeprazole)

Omeprazole irreversibly blocks the gastric H+/K+ ATPase (proton pump) in stomach parietal cells, preventing the final step of acid secretion. This leads to a sustained reduction in gastric acidity, allowing damaged mucosa to heal and reducing reflux symptoms.

The appropriate dose of Lappoxo is determined by the prescribing clinician based on the patient’s condition, severity, and response to therapy. Dosage regimens may vary, and the prescriber will provide specific instructions.

Safety data for omeprazole in pregnancy and lactation are limited. Clinicians should weigh potential benefits against possible risks and consider alternative therapies when appropriate. Women who are pregnant, planning pregnancy, or breastfeeding should discuss use with their healthcare provider.

To request Lappoxo, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any required import documentation.

Lappoxo (omeprazole) belongs to the proton pump inhibitor class, which provides more potent and longer‑lasting acid suppression than H2‑receptor antagonists such as ranitidine. Compared with other PPIs, omeprazole has a well‑established efficacy and safety profile, though individual response may vary.

Lappoxo should be stored at ambient temperature, below 25 °C, in its original packaging. Protect the product from moisture, excessive heat and direct sunlight to maintain its stability and potency.

Lappoxo is taken orally, usually as a whole tablet or capsule with water. It is generally recommended to swallow the dose before a meal, but patients should follow the specific instructions provided by their prescriber.

Serious risks, though uncommon, include severe allergic reactions (anaphylaxis), Clostridioides difficile‑associated diarrhoea, and low magnesium levels that can lead to muscle weakness or cardiac arrhythmias. Patients should seek immediate medical attention if they experience symptoms of these conditions.

Lappoxo is contraindicated in individuals with known hypersensitivity to omeprazole or any component of the formulation. Caution is advised for patients with severe liver disease, those taking certain interacting medications, and patients who have experienced previous adverse reactions to proton pump inhibitors.